

Total synthesis of aculeatins A and B via a tethered oxa-Michael approach[☆]

S. Chandrasekhar,^{*} Ch. Rambabu and T. Shyamsunder

Organic Division-I, Indian Institute of Chemical Technology, Hyderabad 500 007, India

Received 16 March 2007; revised 27 April 2007; accepted 3 May 2007

Available online 10 May 2007

Abstract—A stereocontrolled total synthesis of aculeatins A and B has been achieved in eight steps and in 15% overall yield. The key feature of this synthetic approach is the application of a Maruoka allylation and tethered intramolecular oxa-Michael reaction to install the required stereocentres on the tetrahydropyran ring.

© 2007 Elsevier Ltd. All rights reserved.

Spirocyclic natural products continue to fascinate synthetic organic chemists due to their challenging architecture, which has to be installed in a stereo- and enantioselective manner. Several spirocyclic natural products have been discovered which possess biological properties.¹ The isolation of aculeatins A **1** and B **2** (Fig. 1) as epimeric spiroacetals² followed by their racemic total synthesis³ happened in quick succession. However, the only total synthesis of this rare natural product in optically pure form was reported very recently by Marco et al. involving asymmetric allylation using chiral diisocampheyl borane, Wacker oxidation and a boron aldol as key reactions.⁴

Our interest is designing strategies towards pyran-containing natural products⁵ has culminated in a practical synthesis of both aculeatins A and B in good yields




Figure 1.

Keywords: Aculeatin; Maruoka allylation; Oxa-Michael reaction; Spirocyclic natural products.


[☆] IICT Communication No. 070315.

^{*} Corresponding author. Tel.: +91 40 27193210; fax: +91 40 27160512; e-mail: srivaric@iict.res.in


(overall yield of about 15%). Retrosynthesis revealed tetradecanal **6** and the known 4-benzyloxyphenyl acetylene **5** as starting materials (Scheme 1).

The aldehyde **6** was subjected to an enantioselective Maruoka allylation⁶ using titanium complex (*S,S*)-**I** and allyltri-*n*-butyltin to furnish the homoallylic alcohol **7** in 86% yield with excellent an enantioselectivity of 98% ee (determined by chiral HPLC).⁷ A one-pot ozonolysis, followed by two-carbon homologation⁸ using ethoxycarbonylmethylene triphenylphosphorane produced the δ -hydroxy- α,β -unsaturated ester **8**, which is set up for the tethered intramolecular oxa-Michael reaction to install the second stereocentre. As anticipated, treatment of **8** with benzaldehyde and potassium *tert*-butoxide at 0 °C in anhydrous THF furnished benzylidene acetal **9** in good yield.⁹ The diastereoselectivity was greater than 95% favouring the more stable *syn*-isomer. The conversion of the ester functionality in **9** to Weinreb amide **4** via acid **10** was uneventful. The addition of lithiated 4-benzyloxyphenyl acetylene¹⁰ **5** furnished alkynone¹¹ **3**. Catalytic hydrogenolysis of the benzylidene, benzyloxy and acetylene groups gave **11** (not isolated) and further treatment with phenyliodonium(III) bis(trifluoroacetate) (PIFA)¹² in acetone–H₂O (9:1) yielded a mixture of aculeatins A and B in a ratio of 5:2, which were separated by column chromatography. All the compounds were fully characterized by NMR, mass and IR spectroscopy¹³ and the spectral data of **1** and **2** were in full agreement with those reported in the literature⁴ (Scheme 2).

In conclusion, a stereodivergent, short, high yielding synthesis of aculeatins A and B, which should be



Scheme 1.



Scheme 2. Reagents and conditions: (a) (*S,S*)-I (10 mol %), $\text{Bu}_3\text{SnCH}_2\text{CH}=\text{CH}_2$, CH_2Cl_2 , -15°C to 0°C , 24 h, 86%; (b) (i) O_3 , CH_2Cl_2 , -78°C , 45 min, then PPh_3 ; (ii) $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$, CH_2Cl_2 , rt, 2 h, 80% (for two steps); (c) PhCHO , *t*-BuOK, THF, 0°C , 45 min, 69%; (d) LiOH, THF– H_2O (3:1) 0°C to rt, 4 h, 91%; (e) $\text{NH}(\text{Me})(\text{OMe})\cdot\text{HCl}$, DCC, Et_3N , DMAP, CH_2Cl_2 , 0°C to rt, 90%; (f) *n*-BuLi, **5**, THF, -78°C to -22°C , 75%; (g) Pd–C, H_2 , EtOAc, rt; (h) $\text{PhI}(\text{OOCCH}_3)_2$, $\text{Me}_2\text{CO}-\text{H}_2\text{O}$ (9:1), rt, 10 min, 52 (two steps), 2.5:1 mixture of aculeatins A and B.

amenable to scale up, has been achieved in an overall yield of 15%.

Acknowledgement

C.R. and T.S. thank the CSIR, New Delhi, for research fellowships.

References and notes

- Brimble, M. A.; Fares, F. A. *Tetrahedron* **1999**, *55*, 7661–7706.
- (a) Heilmann, J.; Mayr, S.; Brun, R.; Rali, T.; Sticher, O. *Helv. Chim. Acta* **2000**, *83*, 2939–2945; (b) Heilmann, J.; Brun, R.; Mayr, S.; Rali, T.; Sticher, O. *Phytochemistry* **2001**, *57*, 1281–1285; (c) Confusion has to be avoided between these two compounds and the coumarin aculeatin, isolated from *Toddalia asiatica* (*T. aculeate*): Ishii, H.; Kobayashi, J. I.; Sakurada, E.; Ishikawa, T. *J. Chem. Soc., Perkin Trans. 1* **1992**, 1681–1684; In addition an alkaloid of undefined structure with name aculeatin was isolated from the *Papaver aculeatum*: Maturova, M.; Pavlaskova, D.; Santavy, F. *Planta Med.* **1966**, *14*, 22–41.
- Wong, Y. S. *Chem. Commun.* **2002**, 686–687.
- (a) Falomir, E.; Alvarez-Bercedo, P.; Carda, M.; Marco, J. A. *Tetrahedron Lett.* **2005**, *46*, 8407–8410; (b) Alvarez-Bercedo, P.; Falomir, E.; Carda, M.; Marco, J. A. *Tetrahedron* **2006**, *62*, 9641–9649.
- (a) Chandrasekhar, S.; Prakash, S. J.; Shyamsunder, T. *Tetrahedron Lett.* **2005**, *46*, 6651–6653; (b) Chandrasekhar, S.; Shyamsunder, T.; Prakash, S. J.; Prabhakar, A.; Jagadeesh, B. *Tetrahedron Lett.* **2006**, *47*, 47–49; (c) Chandrasekhar, S.; Rambabu, Ch.; Prakash, S. J. *Tetrahedron Lett.* **2006**, *47*, 1213–1215.
- (a) Hanawa, H.; Hashimoto, T.; Maruoka, K. *J. Am. Chem. Soc.* **2003**, *125*, 1708–1709; (b) Chandrasekhar, S.; Narsihmulu, Ch.; Sultana, S. S. *Tetrahedron Lett.* **2004**, *45*, 9299–9301.
- Homoallylic alcohol **7** was converted to its 4-nitrobenzoate for determination of the ee by chiral HPLC [chiral cel

- OB-H, *i*PrOH/hexanes (1:99), flow rate 0.4 mL/min, RT = 8.12 (0.89%), 9.15 (99.1%)].
- (a) Hon, Y. S.; Lu, L.; Li, S. Y. *J. Chem. Soc., Chem. Commun.* **1990**, 1627–1628; (b) Two-carbon homologation was also tried using *N*-methoxy-*N*-methyl(triphenylphosphoranylidene)acetamide, but low yield of the product was observed.
 - Evans, D. A.; Gouchet-Prunet, J. A. *J. Org. Chem.* **1993**, *58*, 2446–2453.
 - Furst, M.; Ruck-Braun, K. *Synlett* **2002**, 1991–1994.
 - Fukui, Y.; Bruckner, A. M.; Shin, Y.; Balachandran, R.; Day, B. W.; Curran, D. P. *Org. Lett.* **2006**, *8*, 301–304.
 - For a review on hypervalent iodine compounds, see: (a) Zhadankin, V. V.; Stang, P. J. *Chem. Rev.* **2002**, *102*, 2523–2584; For more recent developments, see: (b) Moriarty, R. M. *J. Org. Chem.* **2005**, *70*, 2893–2903; (c) Wirth, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 3656–3665; For oxidations of phenolic compounds with hypervalent iodine reagents, see: (d) Moriarty, R. M.; Prakash, O. *Org. React.* **2001**, *57*, 327–415; For reagents for oxidative spiroacetalizations of arenes, including hypervalent iodine compounds, see: (e) Rodriguez, S.; Wipf, P. *Synthesis* **2004**, 2767–2783.
 - Representative analytical data: Compound **7**: Waxy white solid; $[\alpha]_D^{25} +5.00$ (*c* 1, CHCl₃); IR (KBr): ν 3346 (br.OH), 2924, 2852 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 5.86–5.72 (m, 1H), 5.13–5.07 (m, 2H), 3.63–3.55 (m, 1H), 2.31–2.23 (m, 1H), 2.15–2.05 (m, 1H), 1.43–1.37 (m, 2H), 1.35–1.25 (m, 22H), 0.88 (t, 3H, *J* = 6.7 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 134.9, 118.0, 70.6, 41.9, 36.8, 31.9, 29.6–29.3 (br, several overlapped signals), 25.6, 22.6, 14.1. (ESI-MS): *m/z* 277 [M+Na]. Compound **9**: Waxy white solid; $[\alpha]_D^{25} +1.50$ (*c* 1, CHCl₃); IR (KBr): ν 2924, 2852, 1727 (ketone C=O), 1106, 1025, 751, 728, 696; ¹H NMR (200 MHz, CDCl₃): δ 7.39–7.34 (m, 2H), 7.27–7.18 (m, 3H), 5.43 (s, 1H), 4.23–4.12 (m, 1H), 4.05 (q, 2H, *J* = 6.9 Hz), 3.75–3.67 (m, 1H), 2.61 (dd, 1H, *J* = 15.6, 6.0 Hz), 2.37 (dd, 1H, *J* = 15.6, 6.0 Hz), 1.65–1.35 (m, 4H), 1.28–1.159 (m, 25H), 0.81 (t, 3H, *J* = 6.9 Hz). ¹³C NMR (50 MHz, CDCl₃): δ 170.4, 138.6, 127.9, 126.1, 100.5, 96.2, 76.6, 73.2, 60.3, 40.9, 36.6, 35.9, 32.0, 29.7 (br, several overlapped signals), 29.4, 25.4, 25.1, 22.7, 14.3, 14.2. (ESI-MS): *m/z* 455.3 [M+Na].